The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| BLUEPRINT MEDICINES CORP | COM | 09627Y109 | 157,768 | 7,393,059 | SH | DFND | 7,393,059 | 0 | 0 | ||
| ELEVEN BIOTHERAPEUTICS INC | COM | 286221106 | 11,668 | 4,841,591 | SH | DFND | 4,841,591 | 0 | 0 | ||
| GLOBAL BLOOD THERAPEUTICS IN | COM | 37890U108 | 622,320 | 14,760,900 | SH | DFND | 14,760,900 | 0 | 0 | ||
| SAGE THERAPEUTICS INC | COM | 78667J108 | 272,664 | 6,442,916 | SH | DFND | 6,442,916 | 0 | 0 | ||
| ZAFGEN INC | COM | 98885E103 | 6,721 | 210,371 | SH | DFND | 210,371 | 0 | 0 | ||